Hong Kong and China markets fall amid Covid-19 concerns even as data shows China’s economic recovery has broadened
- Hang Seng Index dropped 0.7 per cent on Tuesday, while the Shanghai Composite slipped 0.1 per cent
- Chinese retail sales and industrial production rose in November, latest data shows
Hong Kong and China markets fell on Tuesday, as investors weighed concerns about increasing Covid-19 deaths, infections and lockdowns around the world against the roll-out of coronavirus vaccines.
New waves of the pandemic have forced Germany, the Netherlands and London back into stricter lockdowns over the Christmas holidays, while cases in Japan and South Korea have also surged, according to Reuters.
First Covid-19 vaccine administered as US death toll passes 300,000
“Positive vaccine news has been a game changer for markets. We now know we are building a bridge to somewhere, providing clarity for policymakers, households and companies about getting to a post Covid-19 stage. Yet, disappointing jobs data in recent weeks points to near-term risks, as the virus surges around the US, potentially slowing the restart,” analysts led by Jean Boivin, head of BlackRock Investment Institute, said in a note.
Fourth wave of coronavirus cases in Hong Kong prompts tougher Covid-19 measures
Power tools giant Techtronic Industries led the declines among blue chips, falling 3.6 per cent. Of the 52 constituent members of the benchmark Hang Seng Index, 36 recorded declines.
The new shares of coronavirus drugs research firm WuXi Biologics, which emerged after a stock split last month, also gained 3.6 per cent. CSPC Pharmaceutical rose 4.4 per cent.
Blue Moon Group, the detergent maker backed by Asian private-equity manager Hillhouse Capital, received strong demand for its initial public offering in Hong Kong, with the retail tranche being oversubscribed 301 times, according to a filing made to the Hong Kong stock exchange on Tuesday. The international tranche of the listing was oversubscribed 12 times.
Priced at HK$13.16 per share, the Guangzhou-based company raised net proceeds of HK$9.6 billion (U$1.2 billion). Trading in Blue Moon shares will start on Wednesday.
It was up from the 4.3 per cent growth recorded in October and was as expected, with a poll of analysts conducted by Bloomberg having forecast 5 per cent growth. The November growth rate was the highest since the 8 per cent recorded in December 2019.
Industrial production, a gauge of manufacturing, mining and utilities output in the Chinese economy, grew by 7 per cent from a year earlier, up slightly from 6.9 per cent in October, and in line with analysts’ expectations. The November growth rate was the highest since it reached 8.5 per cent in March 2019.
Three companies began trading on mainland bourses on Tuesday. In Shenzhen, Hefei Lifeon Pharmaceutical, which produces and sells drugs, rose 44 per cent to 33.31 yuan from its listing price of 23.13 yuan. In Shanghai, West Shanghai Automotive Service, which provides warehousing and transport services, gained 44 per cent to 23.23 yuan from its IPO price of 16.13 yuan. Shuhua Sports, which manufactures sports goods and fitness products, rose 44 per cent to 10.47 yuan from its listing price of 7.27 yuan.
Markets in Asia-Pacific also declined. South Korea’s Kospi fell 0.2 per cent, while Japan’s Nikkei 225 dropped 0.2 per cent. Australia’s S&P/ASX200 also declined 0.4 per cent.
Additional reporting by Georgina Lee